Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$14.49
-0.35-2.36%
At close: -
$14.52
0.030.21%
After Hours: 4:00 PM EDT
Comments
Loading...
Edgewise Therapeutics Analyst Ratings and Price Targets | NASDAQ:EWTX | Benzinga
Edgewise Therapeutics Inc has a consensus price target of $36.22 based on the ratings of 9 analysts. The high is $52 issued by RBC Capital on April 3, 2025. The low is $5 issued by Goldman Sachs on August 25, 2022. The 3 most-recent analyst ratings were released by Wedbush, RBC Capital, and Scotiabank on April 21, 2025, April 3, 2025, and April 3, 2025, respectively. With an average price target of $36.33 between Wedbush, RBC Capital, and Scotiabank, there's an implied 150.23% upside for Edgewise Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
RBC Capital
Scotiabank
Piper Sandler
Stifel
1calculated from analyst ratings
Analyst Ratings for Edgewise Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/21/2025 | Buy Now | 196.14% | Wedbush | Laura Chico50% | $43 → $43 | Maintains | Outperform | Get Alert |
| 04/03/2025 | Buy Now | 258.13% | RBC Capital | Leonid Timashev37% | $56 → $52 | Maintains | Outperform | Get Alert |
| 04/03/2025 | Buy Now | -3.58% | Scotiabank | Louise Chen55% | $50 → $14 | Downgrade | Sector Outperform → Sector Perform | Get Alert |
| 04/02/2025 | Buy Now | 251.24% | Piper Sandler | Yasmeen Rahimi55% | $51 → $51 | Maintains | Overweight | Get Alert |
| 03/07/2025 | Buy Now | 244.35% | Scotiabank | Louise Chen55% | → $50 | Initiates | → Sector Outperform | Get Alert |
| 03/04/2025 | Buy Now | 285.67% | RBC Capital | Leonid Timashev37% | $56 → $56 | Reiterates | Outperform → Outperform | Get Alert |
| 01/22/2025 | Buy Now | 106.61% | Stifel | James Condulis55% | → $30 | Initiates | → Hold | Get Alert |
| 12/17/2024 | Buy Now | 244.35% | Evercore ISI Group | Cory Kasimov67% | $45 → $50 | Maintains | Outperform | Get Alert |
| 11/27/2024 | Buy Now | 244.35% | Truist Securities | Srikripa Devarakonda43% | $33 → $50 | Maintains | Buy | Get Alert |
| 11/22/2024 | Buy Now | 209.92% | Evercore ISI Group | Cory Kasimov67% | → $45 | Initiates | → Outperform | Get Alert |
| 11/08/2024 | Buy Now | 209.92% | Wedbush | Laura Chico50% | $44 → $45 | Maintains | Outperform | Get Alert |
| 10/11/2024 | Buy Now | 251.24% | Piper Sandler | Yasmeen Rahimi55% | $48 → $51 | Maintains | Overweight | Get Alert |
| 09/20/2024 | Buy Now | 189.26% | RBC Capital | Leonid Timashev37% | $32 → $42 | Maintains | Outperform | Get Alert |
| 09/19/2024 | Buy Now | 127.27% | Truist Securities | Srikripa Devarakonda43% | $25 → $33 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 120.39% | RBC Capital | Leonid Timashev37% | $32 → $32 | Maintains | Outperform | Get Alert |
| 08/16/2024 | Buy Now | 113.5% | Wedbush | Laura Chico50% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 113.5% | JP Morgan | Tessa Romero56% | $30 → $31 | Maintains | Overweight | Get Alert |
| 07/25/2024 | Buy Now | 120.39% | RBC Capital | Leonid Timashev37% | $32 → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 07/10/2024 | Buy Now | 120.39% | RBC Capital | Leonid Timashev37% | $32 → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 07/09/2024 | Buy Now | 106.61% | JP Morgan | Tessa Romero56% | $27 → $30 | Maintains | Overweight | Get Alert |
| 07/01/2024 | Buy Now | 230.58% | Piper Sandler | Yasmeen Rahimi55% | $48 → $48 | Maintains | Overweight | Get Alert |
| 06/26/2024 | Buy Now | 113.5% | Wedbush | Laura Chico50% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 04/22/2024 | Buy Now | 120.39% | RBC Capital | Leonid Timashev37% | $28 → $32 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 72.18% | Truist Securities | Srikripa Devarakonda43% | $25 → $25 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 79.06% | Wedbush | Laura Chico50% | $26 → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 92.84% | RBC Capital | Leonid Timashev37% | $28 → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 230.58% | Piper Sandler | Yasmeen Rahimi55% | → $48 | Initiates | → Overweight | Get Alert |
| 11/10/2023 | Buy Now | 58.4% | Wedbush | Laura Chico50% | $27 → $23 | Maintains | Outperform | Get Alert |
| 08/16/2023 | Buy Now | 85.95% | Wedbush | Laura Chico50% | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | Buy Now | 85.95% | Wedbush | Laura Chico50% | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | 72.18% | JP Morgan | Tessa Romero56% | $24 → $25 | Maintains | Overweight | Get Alert |
| 06/28/2023 | Buy Now | 72.18% | Truist Securities | Srikripa Devarakonda43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | 92.84% | RBC Capital | Leonid Timashev37% | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 06/27/2023 | Buy Now | 72.18% | Truist Securities | Srikripa Devarakonda43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 65.29% | JP Morgan | Tessa Romero56% | $25 → $24 | Maintains | Overweight | Get Alert |
| 05/12/2023 | Buy Now | 85.95% | Wedbush | Laura Chico50% | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 05/01/2023 | Buy Now | 72.18% | Truist Securities | Srikripa Devarakonda43% | → $25 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 72.18% | JP Morgan | Tessa Romero56% | $27 → $25 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 99.72% | RBC Capital | Leonid Timashev37% | $31 → $29 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | -65.56% | Goldman Sachs | Madhu Kumar72% | → $5 | Downgrade | Neutral → Sell | Get Alert |
FAQ
What is the target price for Edgewise Therapeutics (EWTX) stock?
The latest price target for Edgewise Therapeutics (NASDAQ:EWTX) was reported by Wedbush on April 21, 2025. The analyst firm set a price target for $43.00 expecting EWTX to rise to within 12 months (a possible 196.14% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Edgewise Therapeutics (EWTX)?
The latest analyst rating for Edgewise Therapeutics (NASDAQ:EWTX) was provided by Wedbush, and Edgewise Therapeutics maintained their outperform rating.
When was the last upgrade for Edgewise Therapeutics (EWTX)?
There is no last upgrade for Edgewise Therapeutics
When was the last downgrade for Edgewise Therapeutics (EWTX)?
The last downgrade for Edgewise Therapeutics Inc happened on April 3, 2025 when Scotiabank changed their price target from $50 to $14 for Edgewise Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Edgewise Therapeutics (EWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewise Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewise Therapeutics was filed on April 21, 2025 so you should expect the next rating to be made available sometime around April 21, 2026.
Is the Analyst Rating Edgewise Therapeutics (EWTX) correct?
While ratings are subjective and will change, the latest Edgewise Therapeutics (EWTX) rating was a maintained with a price target of $43.00 to $43.00. The current price Edgewise Therapeutics (EWTX) is trading at is $14.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
